Royalty Pharma plc vs Eli Lilly & Co.
RPRX vs LLY — side-by-side comparison from reported financials. RPRX leads 4, LLY leads 8 of 12 comparable metrics.
Royalty Pharma plc
RPRX · Healthcare
$56.93+1.28%Solid
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | RPRX | LLY |
|---|---|---|
| Price | $56.93 | $1 177.20 |
| Market cap | $25.4B | $1.05T |
| Revenue (TTM) | $2.54B | $79.7B |
| Revenue growth | +2.1% | +31.7% |
| Net margin | 32.1% | 33.5% |
| Free cash flow | $2.98B | $18.2B |
| Net cash (debt) | ($7.93B) | ($35.2B) |
| 1-year price return | +57.5% | +37.6% |
| P/E | 40.2 | 41.6 |
| P/E vs own history (cheap-side %) | 53% | 88% |
| Dividend yield | 1.22% | 0.52% |
| Return on equity | 12% | 93% |
| Altman Z-score | 2.32 | 7.10 |
| CV checks passed | 10 of 11 | 11 of 11 |
| Employees | 100 | 50,000 |
Full résumé-style profiles: RPRX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.